JP6748175B2 - メチレンブルー混合物を含むパッチ型創傷被覆材 - Google Patents
メチレンブルー混合物を含むパッチ型創傷被覆材 Download PDFInfo
- Publication number
- JP6748175B2 JP6748175B2 JP2018213092A JP2018213092A JP6748175B2 JP 6748175 B2 JP6748175 B2 JP 6748175B2 JP 2018213092 A JP2018213092 A JP 2018213092A JP 2018213092 A JP2018213092 A JP 2018213092A JP 6748175 B2 JP6748175 B2 JP 6748175B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- methylene blue
- wound dressing
- mixture
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 title claims description 116
- 229960000907 methylthioninium chloride Drugs 0.000 title claims description 116
- 239000000203 mixture Substances 0.000 title claims description 94
- 208000027418 Wounds and injury Diseases 0.000 claims description 54
- 206010052428 Wound Diseases 0.000 claims description 53
- 150000007524 organic acids Chemical class 0.000 claims description 49
- 239000000499 gel Substances 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 18
- 229940093915 gynecological organic acid Drugs 0.000 claims description 17
- 235000005985 organic acids Nutrition 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000000416 hydrocolloid Substances 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 230000029663 wound healing Effects 0.000 claims description 12
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 10
- 229960000401 tranexamic acid Drugs 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 239000003617 indole-3-acetic acid Substances 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 9
- 239000005642 Oleic acid Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004380 Cholic acid Substances 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 6
- 235000019416 cholic acid Nutrition 0.000 claims description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 6
- 229960002471 cholic acid Drugs 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- 229960004488 linolenic acid Drugs 0.000 claims description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 6
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 claims description 5
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 5
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 5
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 5
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 5
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 5
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 5
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 claims description 5
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 5
- 229940099347 glycocholic acid Drugs 0.000 claims description 5
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 5
- 229920006264 polyurethane film Polymers 0.000 claims description 5
- 229930002330 retinoic acid Natural products 0.000 claims description 5
- 229960000953 salsalate Drugs 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims description 5
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 claims description 3
- ONZSVEBOAPELKQ-UHFFFAOYSA-N 2-methoxybenzoic acid Chemical compound COC1=CC=CC=C1C(O)=O.COC1=CC=CC=C1C(O)=O ONZSVEBOAPELKQ-UHFFFAOYSA-N 0.000 claims description 3
- XTILJCALGBRMPR-UHFFFAOYSA-N 2-phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1.OC(=O)CC1=CC=CC=C1 XTILJCALGBRMPR-UHFFFAOYSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- LSVICRMDTZSTDC-UHFFFAOYSA-N 2-acetyloxybenzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O LSVICRMDTZSTDC-UHFFFAOYSA-N 0.000 claims description 2
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 45
- 206010034972 Photosensitivity reaction Diseases 0.000 description 28
- 208000007578 phototoxic dermatitis Diseases 0.000 description 28
- 231100000018 phototoxicity Toxicity 0.000 description 28
- 238000011156 evaluation Methods 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 241000191967 Staphylococcus aureus Species 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000003504 photosensitizing agent Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 206010072170 Skin wound Diseases 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000002428 photodynamic therapy Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0213—Adhesive bandages or dressings with fluid retention members the fluid retention member being a layer of hydrocolloid, gel forming material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/442—Colorants, dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Description
acid)、オレイン酸(Oleic acid)、デオキシコール酸(Deoxycholic acid)、葉酸(Folic acid)、レチノイン酸(Retinoic acid)、コール酸(Cholic acid)、グリココール酸(Glycocholic acid)、タウロコール酸(Taurocholic acid)、ケノ−デオキシコール酸(Chenodeoxycholic acid)、グリコケノ−デオキシコール酸(Glycochenodeoxycholic acid)、タウロケノ−デオキシコール酸(Taurochenodeoxycholic acid)、リトコール酸(Lithocholic acid)、サリチルサリチル酸(Salicylsalicylic acid)、アセチルサリチル酸(Acetylsalicylic acid)、メチルサリチル酸(Methylsalicylic acid)、フェニル酢酸(Phenylacetic acid)のうちで選択して使用されて、前記メチレンブルーと前記有機酸成分を複合した時にメチレンブルーと有機酸成分はお互いに物理的に結合して混合物を形成する。
acid)、コール酸(Cholic acid)、グリココール酸(Glycocholic acid)、タウロコール酸(Taurocholic acid)、ケノ−デオキシコール酸(Chenodeoxycholic acid)、グリコケノ−デオキシコール酸(Glycochenodeoxycholic acid)、タウロケノ−デオキシコール酸(Taurochenodeoxycholic acid)、リトコール酸(Lithocholic acid)、サリチルサリチル酸(Salicylsalicylic acid)、アセチルサリチル酸(Acetylsalicylic acid)、メチルサリチル酸(Methylsalicylic acid)、フェニル酢酸(Phenylacetic acid)が挙げられ、下記に表示した化学式1乃至22によってそれぞれ表示される化合物であり、一番望ましくは、サリチル酸とオレイン酸を利用したメチレンブルー混合物である。
(1)静電気力によるメチレンブルー/DHAの疎水化
メチレンブルー(MB、Aldrichで購入)20mgと、DHA(D、Aldrichで購入)20mgをテトラヒドロフラン(THF、大正化学で購入)50mLで60乃至90℃で1乃至5分間加熱してメチレンブルーを溶解させる。メチレンブルーが溶解された混合物を、疎水性注射濾過器(0.2um)を使って濾過し、得られた濾過液を乾燥させる。クロロホルム及び水を利用して有機層に溶けている疎水化されたメチレンブルーを抽出して精製後、凍結乾燥させてMBD(DHAで疎水化されたメチレンブルー)を得た。
メチレンブルー(MB、Aldrichで購入)20mgと、IAA(I、Aldrichで購入)20mgを
テトラヒドロフラン(THF、大正化学で購入)50mLで60乃至90℃で1乃至5分間加熱してメチレンブルーを溶解させる。メチレンブルーが溶解された混合物を、疎水性注射濾過器(0.2um)を使って濾過し、得られた濾過液を乾燥させる。クロロホルム及び水を利用して有機層に溶けている疎水化されたメチレンブルーを抽出して精製後、凍結乾燥させてMBI(IAAで疎水化されたメチレンブルー)を得た。
メチレンブルー(MB、Aldrichで購入)20mgと、Tranexamic acid(T、Aldrichで購入)20mgをテトラヒドロフラン(THF、大正化学で購入)50mLで60乃至90℃で1乃至5分間加熱してメチレンブルーを溶解させる。メチレンブルーが溶解された混合物を、疎水性注射濾過器(0.2um)を使って濾過し、得られた濾過液を乾燥させる。クロロホルム及び水を利用して有機層に溶けている疎水化されたメチレンブルーを抽出して精製後、凍結乾燥させてMBT(Tranexamic acidで疎水化されたメチレンブルー)を得た。
メチレンブルー(MB、Aldrichで購入)20mgと、サリチル酸塩(S、Aldrichで購入)20mgをテトラヒドロフラン(THF、大正化学で購入)50mLで60乃至90℃で1乃至5分間加熱してメチレンブルーを溶解させる。メチレンブルーが溶解された混合物を、疎水性注射濾過器(0.2um)を使って濾過し、得られた濾過液を乾燥させる。クロロホルム及び水を利用して有機層に溶けている疎水化されたメチレンブルーを抽出して精製後、凍結乾燥させてMBS(サリチル酸塩で疎水化されたメチレンブルー)を得た。
メチレンブルー(MB、Aldrichで購入)20mgと、Ascorbic acid(A、Aldrichで購入)20mgをテトラヒドロフラン(THF、大正化学で購入)50mLで60乃至90℃で1乃至5分間加熱してメチレンブルーを溶解させる。メチレンブルーが溶解された混合物を、疎水性注射濾過器(0.2um)を使って濾過し、得られた濾過液を乾燥させる。クロロホルム及び水を利用して有機層に溶けている疎水化されたメチレンブルーを抽出して精製後、凍結乾燥させてMBA(Ascorbic acidで疎水化されたメチレンブルー)を得た。
各有機酸によって疎水化されたメチレンブルー(MBD、MBI、MBT、MBS、MBA)と両親性物質を含んだ混合物製造及びその評価
前記実施例2(1)で得たMBDの0.2mgをオレイン酸塩(Aldrichで購入)の20mgが溶けている水溶液2mLを利用して混合物(MBDs)を製造した。
れたメチレンブルーの効率的混合物形成が可能であることを確認した。
(1)黄色ブドウ球菌を利用した光毒性評価
[1]MBDsの光毒性評価
前記実施例1と実施例2を通じて製造した混合物(MBDs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。10分後光毒性評価のためにHealite II633((株)ルトロニックで購入)を使って10分間(Intensity 4)光を照射する。光照射が終わった各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。
前記実施例1と実施例2を通じて製造した混合物(MBIs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。10分後光毒性評価のためにHealite IIII633((株)ルトロニックで購入)を使って10分間(Intensity 4)光を照射する。光照射が終わった各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。
前記実施例1と実施例2を通じて製造した混合物(MBTs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。10分後光毒性評価のためにHealite II633((株)ルトロニックで購入)を使って10分間(Intensity4)光を照射する。光照射が終わった各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。
前記実施例1と実施例2を通じて製造した混合物(MBSs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg
/mL、0mg/mL)。10分後光毒性評価のためにHealite II633((株)ルトロニックで購入)を使って10分間(Intensity4)光を照射する。光照射が終わった各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。
前記実施例1と実施例2を通じて製造した混合物(MBAs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。10分後光毒性評価のためにHealite II633((株)ルトロニックで購入)を使って10分間(Intensity4)光を照射する。光照射が終わった各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。
[1]MBDsの暗毒性評価
前記実施例1と実施例2を通じて製造した混合物(MBDs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。対照実験で混合物の各濃度に該当するメチレンブルー水溶液を準備して前記実施例3(1) [1]と等しい過程を経って菌数を測定した。前記すべての過程は光が遮られた暗室で実施した。
前記実施例1と実施例2を通じて製造した混合物(MBIs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。対照実験で混合物の各濃度に該当するメチレンブルー水溶液を準備して前記実施例3(1) [2]と等しい過程を経って菌数を測定した。前記すべての過程は光が遮られた暗室で実施した。
前記実施例1と実施例2を通じて製造した混合物(MBTs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。対照実験で混合物の各濃度に該当するメチレンブルー水溶液を準備して前記実施例3(1) [3]と等
しい過程を経って菌数を測定した。前記すべての過程は光が遮られた暗室で実施した。
前記実施例1と実施例2を通じて製造した混合物(MBSs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。対照実験で混合物の各濃度に該当するメチレンブルー水溶液を準備して前記実施例3(1)[4]と等しい過程を経って菌数を測定した。前記すべての過程は光が遮られた暗室で実施した。
前記実施例1と実施例2を通じて製造した混合物(MBTs)が濃度によって菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)1X106個/mLが分散された培養液(LB培地)1mLずつを培養皿(12well-plate)の各ウェル(well)に入れて混合物を濃度別に0.5mLずつ入れる(最終濃度40.4mg/mL、20.2mg/mL、8.08mg/mL、4.04mg/mL、0mg/mL)。各濃度別菌を1X10-6で希釈してペトリフィルム(Petrifilm、3Mで購入)に1mLずつ接種して培養器(37℃)で24時間培養後菌数を測定した。対照実験で混合物の各濃度に該当するメチレンブルー水溶液を準備して前記実施例3(1)[5]と等しい過程を経って菌数を測定した。前記すべての過程は光が遮られた暗室で実施した。
親水コロイドゲルを利用して横10cm、縦10cmの四角形のパッチ型経皮剤を製造し、前記経皮剤にメチレンブルーとサリチル酸及びオレイン酸を混合して形成されたメチレンブルー混合物を単位面積横1cm、縦1cm当たり30μgで均一に塗布した。以後、前記混合物が均一に塗布された親水コロイドゲルを乾燥して前記メチレンブルー混合物を含んだ創傷被覆材を製造した。
(1)黄色ブドウ球菌を利用した光毒性評価
前記実施例4を通じて製造したメチレンブルー混合物含有創傷被覆材が菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)を接種させた寒天培地を準備して、培養皿(12well-plate)の各ウェル(well)にメチレンブルー混合物含有創傷被覆材をメチレンブルー混合物の塗布面を寒天培地に接触させる。10分後光毒性評価のためにHealite II633((株)ルトロニックで購入)を使って10分間(Intensity 4)光を照射する。光照射が終わった後各創傷被覆材をとり除いて培養器(37℃)で24時間培養後菌数を測定した。
前記実施例4を通じて製造したメチレンブルー混合物含有創傷被覆材が菌に及ぶ光毒性を評価するために黄色ブドウ球菌(S.aureus)を接種させた寒天培地を準備して、培養皿(
12well-plate)の各ウェル(well)にメチレンブルー混合物含有創傷被覆材をメチレンブルー混合物の塗布面を寒天培地に接触させる。10分後暗毒性評価のために各創傷被覆材をとり除いて培養器(37℃)で24時間培養後菌数を測定した。
Claims (4)
- 肌の損傷部位の保護及び感染防止のための創傷被覆材に関するものであり、前記創傷被覆材を肌に付着するための経皮剤と前記経皮剤に創傷治癒のための組成物としてメチレンブルーと二種類の有機酸1及び有機酸2との混合物が塗布されたことを特徴とする肌の損傷部位の保護及び感染防止のための創傷被覆材であって
前記有機酸1は、ドコサヘキサエン酸(DHA:docosahexaenoic acid)、インドール-3-酢酸(IAA:indole-3-acetic、acid)、トラネキサム酸(Tranexamic acid)、サリチル酸(Salicylic acid)、アスコルビン酸(Ascorbic acid)、リノール酸(Linoleic acid)、リノレン酸(Linolenic acid)、オレイン酸(Oleic acid)、デオキシコール酸(Deoxycholic acid)、葉酸(Folic acid)、レチノイン酸(Retinoic acid)、コール酸(Cholic acid)、グリココール酸(Glycocholic acid)、タウロコール酸(Taurocholic acid)、ケノ−デオキシコール酸(Chenodeoxycholic acid)、グリコケノ−デオキシコール酸(Glycochenodeoxycholic acid)、タウロケノ−デオキシコール酸(Taurochenodeoxycholic acid)、リトコール酸(Lithocholic acid)、サリチルサリチル酸(Salicylsalicylic acid)、アセチルサリチル酸(Acetylsalicylic acid)、メチルサリチル酸(Methylsalicylic acid)、フェニル酢酸(Phenylacetic acid)から選択され、
前記有機酸2は、オレイン酸(Oleic acid)であり、
前記メチレンブルー及び前記2種類の有機酸はミセル構造を形成し、前記メチレンブルーと一つの有機酸は中央に位置し、他の有機酸は外側に位置し、
前記メチレンブルーと前記二種類の有機酸との質量比は、前記有機酸1の質量が前記メチレンブルーの質量の1〜5倍であり、前記有機酸2の質量が前記メチレンブルーと有機酸1との混合物の質量の50〜500倍である創傷被覆材。 - 前記経皮剤は親水コロイドゲル、ポリウレタンフィルム、PVAハイドロゲル、アルギン酸ナトリウムゲルのうちで選択された何れか一つでなされたことを特徴とする請求項1に記載の肌の損傷部位の保護及び感染防止のための創傷被覆材。
- 前記創傷被覆材に塗布されたメチレンブルーと有機酸1及び有機酸2との混合物は、前記経皮剤の単位面積横1cm、縦1cm当たり0.1乃至100μgが含まれたことを特徴とする請求項1に記載の肌の損傷部位の保護及び感染防止のための創傷被覆材。
- 前記創傷被覆材に塗布されたメチレンブルーと有機酸1及び有機酸2との混合物は、前記経皮剤の単位面積横1cm、縦1cm当たり10乃至50μgが含まれたことを特徴とする請求項1に記載の肌の損傷部位の保護及び感染防止のための創傷被覆材。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0007575 | 2018-01-22 | ||
KR1020180007575A KR102012581B1 (ko) | 2018-01-22 | 2018-01-22 | 메틸렌블루 혼합물을 포함하는 패치형 창상피복재 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019126713A JP2019126713A (ja) | 2019-08-01 |
JP6748175B2 true JP6748175B2 (ja) | 2020-08-26 |
Family
ID=64665139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018213092A Active JP6748175B2 (ja) | 2018-01-22 | 2018-11-13 | メチレンブルー混合物を含むパッチ型創傷被覆材 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10695300B2 (ja) |
EP (1) | EP3513819B1 (ja) |
JP (1) | JP6748175B2 (ja) |
KR (1) | KR102012581B1 (ja) |
CN (1) | CN109966537B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110818941B (zh) * | 2019-10-08 | 2022-03-29 | 淮阴工学院 | 一种近红外光响应型杀菌-脱粘附褶皱表面的制备方法 |
CN111001028B (zh) * | 2019-12-29 | 2021-09-10 | 北京工商大学 | 亚甲基蓝抗氧化修复高分子纳米纤维膜及制备方法 |
US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
KR102386028B1 (ko) | 2021-01-06 | 2022-04-14 | 주식회사 셀바이오휴먼텍 | 전위차 소재를 이용한 전도성 패턴이 구비된 창상피복재 시트 및 그 제조방법 |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3107726B2 (ja) * | 1994-05-13 | 2000-11-13 | 株式会社クラレ | 水膨潤性高分子ゲル |
AU2003290517A1 (en) * | 2002-08-20 | 2004-04-19 | General Wound Kare, Inc. (A Corporation Of Deleware) | Medical pad, and method for making and using |
CA2529413C (en) * | 2003-06-20 | 2014-05-27 | Johnson & Johnson Medical Limited | Antioxidant wound dressing materials |
JP4896714B2 (ja) * | 2003-06-20 | 2012-03-14 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | 抗酸化性の創傷用包帯材料 |
US20090093470A1 (en) * | 2007-10-08 | 2009-04-09 | Ondine International, Ltd. | Photodynamic therapy process and photosensitizer compositions therefor |
BRPI0822305B8 (pt) | 2008-02-25 | 2021-06-22 | Teikoku Seiyaku Kk | material de hidrogel protetor de feridas |
US8389583B2 (en) * | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
EA026962B1 (ru) * | 2008-11-07 | 2017-06-30 | Клокс Текнолоджиз Инк. | Композиция и способ для лечения красных угрей |
GB0900326D0 (en) * | 2009-01-09 | 2009-02-11 | Barker Stephen G E | Gel layer |
CZ303548B6 (cs) * | 2011-01-05 | 2012-11-28 | Contipro Pharma A.S. | Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje |
EP2524705B1 (de) * | 2011-05-19 | 2014-04-23 | Lohmann & Rauscher GmbH & Co. KG | Sterile Wundauflage mit einem synthethischen Dreiblock-Elastomer und einem hydrophorbierten polymeren Biguanid |
JP2014091037A (ja) * | 2012-11-05 | 2014-05-19 | Alcare Co Ltd | 創傷被覆材及びそれを用いた光創傷治療装置 |
US20140276354A1 (en) * | 2013-03-14 | 2014-09-18 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
KR20150111705A (ko) * | 2014-03-26 | 2015-10-06 | 한국과학기술연구원 | 생체영상 및 광역학 치료를 위한 메틸렌 블루 나노 입자 및 이의 용도 |
KR101667404B1 (ko) | 2014-09-11 | 2016-10-19 | 중앙대학교 산학협력단 | 광반응성 젤라틴 유도체에 단백질 약물이 고정되어 있는 창상피복재 및 그 제조방법 |
US11491255B2 (en) * | 2015-04-06 | 2022-11-08 | 3M Innovative Properties Company | Removable film forming gel compositions and methods for their application |
US9867787B2 (en) * | 2015-04-27 | 2018-01-16 | The University Of Hong Kong | Hypromellose-graft-chitosan and methods thereof for sustained drug delivery |
KR101822154B1 (ko) * | 2016-06-20 | 2018-01-26 | (주)뷰티화장품 | 여드름 치료 및 개선용 조성물 |
KR101988240B1 (ko) * | 2017-02-27 | 2019-06-12 | 주식회사 디알나노 | 피부질환에 사용되는 메틸렌 블루 복합체 및 이의 용도 |
-
2018
- 2018-01-22 KR KR1020180007575A patent/KR102012581B1/ko active IP Right Grant
- 2018-10-23 US US16/167,563 patent/US10695300B2/en active Active
- 2018-11-13 JP JP2018213092A patent/JP6748175B2/ja active Active
- 2018-12-04 CN CN201811470613.6A patent/CN109966537B/zh active Active
- 2018-12-12 EP EP18211988.3A patent/EP3513819B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3513819A1 (en) | 2019-07-24 |
JP2019126713A (ja) | 2019-08-01 |
US10695300B2 (en) | 2020-06-30 |
US20190224134A1 (en) | 2019-07-25 |
KR102012581B1 (ko) | 2019-08-20 |
EP3513819B1 (en) | 2021-02-03 |
CN109966537B (zh) | 2021-08-27 |
CN109966537A (zh) | 2019-07-05 |
KR20190089303A (ko) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6748175B2 (ja) | メチレンブルー混合物を含むパッチ型創傷被覆材 | |
CN206214465U (zh) | 皮肤或创面复合敷料及其套件 | |
Zhou et al. | Rational design of intelligent and multifunctional dressing to promote acute/chronic wound healing | |
Yuan et al. | Chitosan, alginate, hyaluronic acid and other novel multifunctional hydrogel dressings for wound healing: A review | |
CN105012993A (zh) | 一种阳离子医用生物胶抗菌敷料及其制备方法 | |
US20080020025A1 (en) | Composition for wound care and method of using same | |
CN109646712B (zh) | 一种胶态硫液体敷料及其制备方法 | |
CN108785739A (zh) | 一种多功能液体创可贴及其制备方法 | |
Viswanathan et al. | Chlorhexidine-calcium phosphate nanoparticles—Polymer mixer based wound healing cream and their applications | |
EA014391B1 (ru) | Фармацевтическая композиция для лечения ожогов и способ ее получения | |
WO2017019503A1 (en) | Wound care products comprising alexidine | |
WO2014041440A1 (en) | Honey-based dressing for the treatment of wounds and burns | |
Elkenawy et al. | Development of gamma irradiated SSD-embedded hydrogel dyed with prodigiosin as a smart wound dressing: Evaluation in a MDR infected burn rat model | |
WO2017030388A9 (ko) | 피부 상처 치료조성물 | |
RU2636530C2 (ru) | Фармацевтическая композиция для лечения ран и ожогов | |
CN107595819B (zh) | 一种纳米金刚石改性液体创可贴及其制备方法 | |
US20110165276A1 (en) | Composition for burn treatment | |
RU2416425C1 (ru) | Масло противопролежневое | |
JP2020528404A (ja) | 皮膚病変の治療における局所適用のためのフィルム、およびそれを得る方法ならびに適用方法 | |
EP1986617A2 (en) | Extraction, preparation and use of active principles of the aloe plant to realize of self-medication devices such as aloe controlled-release gauzes, bandages, stockings, elastic bands and arch supports | |
RU2733137C1 (ru) | Способ получения биокомпозита с регенерационными свойствами на основе гидрогеля бактериальной целлюлозы | |
CN105126149A (zh) | 一种医用复合壳聚糖敷贴 | |
RU2195262C2 (ru) | Фармакологическое средство на основе гиалуроновой кислоты, обладающее антимикробным, ранозаживляющим и противовоспалительным действием | |
Karayel et al. | Antimicrobial wound dressing materials | |
CN111821504B (zh) | 一种银离子消毒凝胶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181204 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200804 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200806 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6748175 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |